drugset / Trial / NCT00243867
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus carboplatin in a prospectively randomized trial. In addition, the response rate to each regimen, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.
Timeline
- Start
- 2005-11
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | PACLITAXEL DOCOSAHEXAENOIC ACID | Small molecule | 400 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 225 mg/m2 | Intravenous |